Form D · Pharmaceuticals

Tivorsan Pharmaceuticals, Inc.

Los Angeles, CA · CIK 0001705703

Offering snapshot reported Oct 25, 2018 · SEC filing

Reported sold
$1.12M
Offering amount: $1.12M
Investors reported
2
Form D · investor count
Minimum accepted
$250K
Reported outside-investor minimum
First sale
Feb 23, 2011
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 25, 2018Initial$1,124,824No comparison2SEC filing
Oct 25, 2018Initial$2,767,751No comparison14SEC filing
Oct 25, 2018Initial$1,636,250No comparison8SEC filing
Oct 25, 2018Initial$4,474,000No comparison32SEC filing
Oct 25, 2018Initial$2,938,000No comparison35SEC filing
Oct 25, 2018Initial$900,000No comparison4SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-324378

Source: Form D, filed Oct 25, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Joel Braunstein Director
James Connolly Director
Justin Fallon Director
Michael Meyers Executive
John Nicholson Director
Jay Venkatesan Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
2049 Century Park East Suite 320
Los Angeles, CA, 90067